Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 701–800 of 1,002
Coomber, B., O’Donoghue, M., & Mason, R. J. (2008) · Synapse · doi:10.1002/syn.20547 · Cited by 42
“The potent inhibitor of FAAH enzyme activity, cyclohexylcarbamic acid 3 0 -carbamoyl-biphenyl-3-yl ester (URB597) (Kathuria et al., 2003), was used to block the metabolism of AEA, and was coadministered with KA.”
BackgroundMethodPathophysiology and Pharmacology of GABAA Receptors
Möhler, H., Fritschy, J., Vogt, K. E., Crestani, F., & Rudolph, U. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-28082-0_9 · Cited by 44
Justinová, Z., Panlilio, L. V., & Goldberg, S. R. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_13 · Cited by 48
“…found that anandamide alone had no effects on place conditioning, but it induced conditioned place aversion when its metabolism was inhibited by the selective FAAH inhibitor URB597, which by itself does not produce conditioned place preference or aversion (Gobbi et al. 2005; Kathuria et al. 2003).”
BackgroundToward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics
Yu, H. S., Gao, C., Lupyan, D., Wu, Y., Kimura, T., Wu, C., Jacobson, L., Harder, E., Abel, R., & Wang, L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00268 · Cited by 39
Pillolla, G., Melis, M., Perra, S., Muntoni, A. L., Gessa, G. L., & Pistis, M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0733-z · Cited by 43
“URB597 rapidly increases brain anandamide levels (Kathuria et al. 2003).”
Starowicz, K., & Marzo, V. D. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.075 · Cited by 43
“(and, unexpectedly, 2-AG), only the lower dose ofthe inhibitor attenuated hyperalgesia, supporting earlier reports that FAAH inhibitors are anti-nociceptive in models of acute inflammatory pain (Kathuria et al., 2003; Jayamanne et al., 2006; Lichtman et al., 2004a).”
BackgroundResultRoohbakhsh, A., Keshavarz, S., Hasanein, P., Rezvani, M. E., & Moghaddam, A. H. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00449.x · Cited by 42
Rahman, I. A. S., Tsuboi, K., Hussain, Z., Yamashita, R., Okamoto, Y., Uyama, T., Yamazaki, N., Tanaka, T., Tokumura, A., & Ueda, N. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.09.008 · Cited by 40
“URB597 was used to inhibit fatty acid amide hydrolase, an enzyme degrading N-acylethanolamines [22,23].”
MethodPanlilio, L. V., & Justinová, Z. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.193 · Cited by 39
Schmidt, W., Schäfer, F., Striggow, V., Fröhlich, K., & Striggow, F. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.080 · Cited by 44
Vlachou, S., Stamatopoulou, F., Nomikos, G. G., & Panagis, G. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008717 · Cited by 40
“various behavioural paradigms (see e.g. Compton and Martin, 1997 ; de Lago et al., 2004 ; Kathuria et al., 2003), only a few studies have examined their possible reinforcing/rewarding properties (Bortolato et al.”
BackgroundKangas, B. D., Leonard, M. Z., Shukla, V., Alapafuja, S. O., Nikas, S. P., Makriyannis, A., & Bergman, J. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228189 · Cited by 39
Haller, V. L., Cichewicz, D. L., & Welch, S. P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.024 · Cited by 42
Guindon, J., LoVerme, J., Piomelli, D., & Beaulieu, P. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000263278.05423.a3 · Cited by 40
“However, propofol was a mild inhibitor of FAAH compared with strong inhibitors like URB532 and URB597 (28).”
BackgroundSelf-citationBrunetti, L., Loiodice, F., Piemontese, L., Tortorella, P., & Laghezza, A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00885 · Cited by 38
Ferber, S. G., Trezza, V., & Weller, A. (2019) · Developmental Psychobiology · doi:10.1002/dev.21944 · Cited by 45
Korff, M., Imberg, L., Will, J. M., Bückreiß, N., Kalinina, S. A., Wenzel, B., Kastner, G. A., Daniliuc, C. G., Barth, M., Ovsepyan, R. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01635 · Cited by 38
The endocannabinoid system – current implications for drug development
Fowler, C. J. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13229 · Cited by 42
Maciel, I. D. S., de Abreu, G. H. D., Johnson, C. T., Bonday, R., Bradshaw, H. B., Mackie, K., & Lu, H. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0015 · Cited by 40
“55 FAAH inhibition by URB597 reverses social deficits following PCE in rats.”
The Endocannabinoid System as a Pharmacological Target for New Cancer Therapies
Ramer, R., Wittig, F., & Hinz, B. (2021) · Cancers · doi:10.3390/cancers13225701 · Cited by 39
“This was later followed by URB597, a more potent FAAH inhibitor that even increased AEA levels in the brain, thereby exhibiting benzodiazepine-like properties [22].”
BackgroundIzawa, Y., Zheng, C., & Stahl, S. S. (2013) · Angewandte Chemie · doi:10.1002/ange.201209457 · Cited by 39
Forster, L., Ludwig, J., Kaptur, M., Bovens, S., Elfringhoff, A. S., Holtfrerich, A., & Lehr, M. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.11.028 · Cited by 38
Crow, J. A., Bittles, V., Borazjani, A., Potter, P. M., & Ross, M. K. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.08.017 · Cited by 38
Holtfrerich, A., Hanekamp, W., & Lehr, M. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.050 · Cited by 38
Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders
Vinod, K. Y., & Hungund, B. L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.2.203 · Cited by 42
“However, blockade of AEA hydrolysis through FAAH inhibition results in anxiolytic responses [57].”
BackgroundDeMartino, J. K., Garfunkle, J., Hochstatter, D. G., Cravatt, B. F., & Boger, D. L. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.084 · Cited by 40
Rojas, M. J. L., Galeano, P., Suárez, J., Araos, P. F., Santín, L. J., de Fonseca, F. R., & Blanco, E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000569 · Cited by 38
Clinical Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v04n01_03 · Cited by 43
Silveira, M. M., Arnold, J. C., Laviolette, S. R., Hillard, C. J., Celorrio, M., Aymerich, M. S., & Adams, W. K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.09.007 · Cited by 43
“For example, the potent inhibitor of FAAH, URB597, induces anxiolytic effects in mice in a CB1 receptordependent manner (Busquets-Garcia et al., 2011; Kathuria et al., 2003).”
BackgroundOkamoto, Y., Morishita, J., Jun, W. A. N. G., Schmid, P. C., Krebsbach, R. J., Schmid, H. H. O., & Ueda, N. (2005) · Biochemical Journal · doi:10.1042/bj20041790 · Cited by 38
Development of highly sensitive fluorescent assays for fatty acid amide hydrolase
Huang, H., Nishi, K., Tsai, H.-J., & Hammock, B. D. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.10.041 · Cited by 39
The endogenous cannabinoid system and the treatment of marijuana dependence
Piomelli, D. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.018 · Cited by 40
“Second, inhibition of FAAH activity in intact neurons and astrocytoma cells prevents the hydrolysis of anandamide, but has no effect on 2-AG degradation (Kathuria et al., 2003).”
BackgroundResultSelf-citationArmirotti, A., Romeo, E., Ponzano, S., Mengatto, L., Dionisi, M., Karacsonyi, C., Bertozzi, F., Garau, G., Tarozzo, G., Reggiani, A. M., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300056y · Cited by 39
Self-citationInvestigational drugs under development for the treatment of PTSD
Ragen, B., Seidel, J., Chollak, C., Pietrzak, R. H., & Neumeister, A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1020109 · Cited by 38
“These include: i) anandamide is a weak, partial CB1 agonist [66] and unlike D(9)-THC has no reinforcing effects [67,68]; ii) FAAH inhibitor treatment is not associated with adverse cognitive side effects [69]; iii) cardiovascular liabilities (tachycardia, orthostasis, syncope) [70]; or iv) hyperphagia [71]; v) the pha…”
BackgroundMurillo‐Rodríguez, E., Machado, S. E. D. C., Rocha, N., Budde, H., Yuan, T., & Arias-Carrión, Ó. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.10.011 · Cited by 38
“Though still incomplete, the limited available data suggest that a putative transporter controls the anandamide trafficking (Cravatt et al., 2001; Kathuria et al., 2003; Makriyannis, 2014; Fezza et al., 2014; Batista et al., 2014; Nicolussi and Gertsch, 2015).”
Inoue, M., Tsuboi, K., Okamoto, Y., Hidaka, M., Uyama, T., Tsutsumi, T., Tanaka, T., Ueda, N., & Tokumura, A. (2017) · The Journal of Biochemistry · doi:10.1093/jb/mvx054 · Cited by 37
Alteba, S., Zer‐Aviv, T. M., Tenenhaus, A., David, G. B., Adelman, J. W., Hillard, C. J., Doron, R., & Akirav, I. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.08.005 · Cited by 40
Scheyer, A. F., Yasmin, F., Naskar, S., & Patel, S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01438-7 · Cited by 40
“Indeed, potent, selective, and brain penetrant or peripherally restricted inhibitors of the AEA degrading enzyme, FAAH [37], have been extensively investigated for almost two decades [38].”
BackgroundLi, H., Wood, J. T., Whitten, K. M., Vadivel, S. K., Seng, S., Makriyannis, A., & Avraham, H. K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12111 · Cited by 38
“URB597 is widely regarded as a specific FAAH inhibitor (Kathuria et al., 2003; Piomelli et al., 2006).”
BackgroundDlugos, A. M., Hamidovic, A., Hodgkinson, C. A., Goldman, D. A., Palmer, A. A., & de Wit, H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.166 · Cited by 39
“In studies with rodents, FAAH inhibitors such as URB597 exert anxiolytic (Kathuria et al, 2002; Moreira et al, 2008; Rubino et al, 2008) and wake-modulating effects such as alertness and Arousal (Murillo-Rodrı́guez et al, 2007).”
Pryce, G., Cabranes, A., Fernández‐Ruíz, J., Bisogno, T., Marzo, V. D., Long, J. Z., Cravatt, B., Giovannoni, G., & Baker, D. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513485982 · Cited by 39
Sadhasivam, S., Zhang, X., Chidambaran, V., Mavi, J., Pilipenko, V. V., Baye, T. M., Meller, J., Kaufman, K. M., Martin, L. J., & McAuliffe, J. J. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.79 · Cited by 40
Anandamide Protects from Low Serum-induced Apoptosis via Its Degradation to Ethanolamine
Matas, D., Juknat, A., Pietr, M., Klin, Y., & Vogel, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608646200 · Cited by 40
Kono, M., Matsumoto, T., Kawamura, T., Nishimura, A., Kiyota, Y., Oki, H., Miyazaki, J., Igaki, S., Behnke, C. A., Shimojo, M., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.006 · Cited by 40
Wyffels, L., Muccioli, G. G., Bruyne, S. D., Moerman, L., Sambre, J., Lambert, D. M., & Vos, F. D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900324e · Cited by 41
Cannabinoids cool the intestine
Kunos, G., & Pacher, P. (2004) · Nature Medicine · doi:10.1038/nm0704-678 · Cited by 37
Karlsson, M., Påhlsson, C., & Fowler, C. J. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.03.009 · Cited by 38
Catalytic asymmetric synthesis of meta benzene isosteres
Zhang, M., Chapman, M., Sarode, B. R., Xiong, B., Liang, H., Chen, J., Weerapana, E., & Morken, J. P. (2024) · Nature · doi:10.1038/s41586-024-07865-4 · Cited by 41
Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase
Liu, P., Hamill, T. G., Chioda, M. D., Chobanian, H. R., Fung, S., Guo, Y., Chang, L. L., Bakshi, R. K., Hong, Q., Dellureficio, J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000996 · Cited by 36
Ahmad, H., Rauf, K., Zada, W., McCarthy, M. M., Abbas, G., Anwar, F., & Shah, A. J. (2020) · Molecules · doi:10.3390/molecules25204683 · Cited by 38
“Likewise, inhibition of AEA metabolism was also reported to occur in anxiety [14].”
BackgroundFAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus
Henry, R. J., Kerr, D. M., Finn, D. P., & Roche, M. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.09.002 · Cited by 40
Iwasaki, S., Ishiguro, H., Higuchi, S., Onaivi, E. S., & Arinami, T. (2007) · Psychiatric Genetics · doi:10.1097/ypg.0b013e32809913d8 · Cited by 39
“…mice and mice treated with FAAH inhibitor had high concentrations of fatty acid amides, including anandamide, in the central nervous system, and these fatty acid amides had analgesic and anxiolytic effects (Cravatt et al., 2001; Clement et al., 2003; Kathuria et al., 2003; Lichtman et al., 2004).”
BackgroundLodola, A., Capoferri, L., Rivara, S., Tarzia, G., Piomelli, D., Mulholland, A. J., & Mor, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301867x · Cited by 36
Self-citationMileni, M., Garfunkle, J., Ezzili, C., Cravatt, B. F., Stevens, R. C., & Boger, D. L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja110877y · Cited by 39
Marco, E. M., Rubino, T., Adriani, W., Viveros, M., Parolaro, D., & Laviola, G. (2008) · Brain Research · doi:10.1016/j.brainres.2008.12.037 · Cited by 36
Simone, A. D., Russo, D., Ruda, G. F., Micoli, A., Ferraro, M., Martino, R. M. C. D., Ottonello, G., Summa, M., Armirotti, A., Bandiera, T., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01578 · Cited by 35
Lau, B. K., Drew, G. M., Mitchell, V. A., & Vaughan, C. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12839 · Cited by 35
“Although numerous functional studies have investigated the analgesic efficacy of FAAH/MGL inhibitors in animal models of pain (Kathuria et al., 2003; Holt et al., 2005; Jayamanne et al., 2006; Russo et al., 2007; Long et al., 2009a), the cellular mechanisms by which these agents enhance endocannabinoid signalling have…”
BackgroundInfluentialHicks, J. W., Parkes, J., Sadovski, O., Tong, J., Houle, S., Vasdev, N., & Wilson, A. A. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.04.008 · Cited by 36
Carr, R. L., Armstrong, N. H., Buchanan, A. T., Eells, J. B., Mohammed, A. N., Ross, M. K., & Nail, C. A. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.11.016 · Cited by 37
“…documented that increasing AEA levels in adult brain, either by genetic deletion or pharmacological inhibition of FAAH activity, leads to anxiolytic behavior in multiple tests of anxiety (Kathuria et al., 2003; Patel and Hillard, 2006; Naidu et al., 2007; Moreira et al., 2008; Kinsey et al., 2011).”
BackgroundFluorine nuclear magnetic resonance-based assay in living mammalian cells
Veronesi, M., Giacomina, F., Romeo, E., Castellani, B., Ottonello, G., Lambruschini, C., Garau, G., Scarpelli, R., Bandiera, T., Piomelli, D., et al. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.11.015 · Cited by 35
“5 h by adding 40 mM of the potent FAAH inhibitor URB597 [40] (see Materials and Methods).”
MethodSelf-citationDisease-Specific Heteromerization of G-Protein-Coupled Receptors That Target Drugs of Abuse
Gomes, I., Fujita, W., Chandrakala, M. V., & Devi, L. A. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386931-9.00009-x · Cited by 35
Gamaleddin, I., Guranda, M., Scherma, M., Fratta, W., Makriyannis, A., Vadivel, S. K., Goldberg, S. R., & Foll, B. L. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113477710 · Cited by 36
“, 2003); (b) AEA accumulation inside the cells is inhibited by AEA uptake inhibitors and increased by some FAAH inhibitors (Kathuria et al., 2003); (c) AEA uptake can still be demonstrated in cells lacking the expression of FAAH (Deutsch et al.”
BackgroundFlannery, L. E., Kerr, D. M., Finn, D. P., & Roche, M. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.06.030 · Cited by 37
The neurochemistry of social reward during development: What have we learned from rodent models?
Manduca, A., Carbone, E., Schiavi, S., Cacchione, C., Buzzelli, V., Campolongo, P., & Trezza, V. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15321 · Cited by 36
“An intriguing strategy to investigate the role of the endocannabinoid AEA in social behavior is to modulate the activity of FAAH enzyme, the main degrading enzyme for AEA in the brain, thus enhancing the biological actions of this endocannabinoid (Cravatt et al. 2001; Kathuria et al. 2003).”
BackgroundHua, D. Y.-H., Hindocha, C., Baio, G., Lees, R., Shaban, N. D. C., Morgan, C. J. A., Mofeez, A., Curran, H. V., & Freeman, T. P. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02410-9 · Cited by 37
“In mouse and rodent models, the experimental elevation of anandamide via exercise or inhibition of FAAH resulted in anxiolytic effects, which were then nullified by CB1R blockade [20, 21].”
BackgroundGlaser, S. T., Deutsch, D. G., Studholme, K. M., ZIMOV, S., & Yazulla, S. (2005) · Visual Neuroscience · doi:10.1017/s0952523805226020 · Cited by 38
“These compounds, along with recently developed selective FAAH inhibitors ~Kathuria et al., 2003; Leung et al., 2003!, could clarify the role FAAH activity plays in regulating AEA uptake in vivo, once their interactions with other proteins are fully characterized.”
BackgroundSadovski, O., Hicks, J. W., Parkes, J., Raymond, R., Nóbrega, J. N., Houle, S., Cipriano, M., Fowler, C. J., Vasdev, N., & Wilson, A. A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.077 · Cited by 35
Carr, R. L., Borazjani, A., & Ross, M. K. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr081 · Cited by 34
“In addition, exposure of adult rodents to the FAAH inhibitor URB597 leads to anxiolyticlike effects, and FAAH knockout mice also exhibit anxiolytic behavior as adults (Haller et al., 2009; Kathuria et al., 2003; Moreira et al., 2008).”
BackgroundSaito, V. M., Wotjak, C. T., & Moreira, F. A. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500004 · Cited by 103
“Also the treatment with the anandamidehydrolysis inhibitor URB597 exerted anxiolytic-like effects similar to benzodiazepines.(30,60,63-65) URB597 showed also antidepressantlike actions in animal models of stress-related psychopathology.”
Recent advances in the cannabinoids
Hertzog, D. L. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.10.1435 · Cited by 34
“Patents (2004) 14(10) 1447 has recently been found to augment the endogenous levels of anandamide and other endocannabinoids 3- to 5-fold, and produce CB1-dependent effects on anxiety and pain [30].”
BackgroundURB754 Has No Effect on the Hydrolysis or Signaling Capacity of 2-AG in the Rat Brain
Saario, S. M., Palomäki, V., Lehtonen, M., Nevalainen, T., Järvinen, T., & Laitinen, J. T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.07.008 · Cited by 34
Wyffels, L., Muccioli, G. G., Kapanda, C. N., Labar, G., Bruyne, S. D., Vos, F. D., & Lambert, D. M. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2010.03.009 · Cited by 36
“Also, the observation that genetic or pharmacological inactivation of FAAH results in anxiolytic [13] and antidepressant [11,41] phenotypes in rodents suggests that FAAH may play an important therapeutic target for these and possibly many other CNS disorders.”
Crombie, K. M., Privratsky, A. A., Schomaker, C. M., Heilicher, M. O., Ross, M. C., Sartin‐Tarm, A., Sellnow, K. A., Binder, E. B., James, G. A., & Cisler, J. M. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102922 · Cited by 34
NSAIDs: eNdocannabinoid stimulating anti-inflammatory drugs?
Fowler, C. J. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.05.003 · Cited by 34
Cannabinoids and Reproduction: A Lasting and Intriguing History
Cacciola, G., Chianese, R., Chioccarelli, T., Ciaramella, V., Fasano, S., Pierantoni, R., Meccariello, R., & Cobellis, G. (2010) · Pharmaceuticals · doi:10.3390/ph3103275 · Cited by 35
“However, URB597 administration in the rat brain reduces AEA degradation, but has not effect on 2-AG levels, thus suggesting that 2-AG hydrolysis proceeds through distinct enzymatic pathway [122].”
BackgroundWojtalla, A., Herweck, F., Granzow, M., Klein, S., Trebicka, J., Huss, S., Lerner, R., Lutz, B., Schildberg, F. A., Knolle, P. A., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00241.2011 · Cited by 39
“Endocannabinoids were initially described to play major roles in the central nervous system where they regulate food intake, emotions, pain perception, and sleep (16, 17, 27).”
Forget, B., Guranda, M., Gamaleddin, I., Goldberg, S. R., & Foll, B. L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4232-y · Cited by 33
“*p < 0.05, **p < 0.01, *p < 0.0001 vs. vehicle + vehicle; #p < 0.05 vs. vehicle + URB597; LSD multiple comparisons following two-way repeated-measures ANOVAs in rats (Forget et al. 2009) and to induce a full, fast, and longlasting inhibition of FAAH (Kathuria et al. 2003).”
BackgroundInfluentialThe potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH
Paylor, B., Holt, S., & Fowler, C. J. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.07.006 · Cited by 33
Bergamaschi, M. M., Queiróz, R. H. C., Chagas, M. H. N., Linares, I. M. P., Arrais, K. C., de Oliveira, D. C. G., Queiroz, M. E. C., Nardi, A. E., Huestis, M. A., Hallak, J. E. C., et al. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2374 · Cited by 35
“Endocannabinoid hydrolysis inhibitors generally induce anxiolytic effects (Kathuria et al., 2003; Patel and Hillard, 2006; Moreira et al., 2008; Haller et al., 2009).”
BackgroundHupli, A. (2018) · Medical Cannabis and Cannabinoids · doi:10.1159/000495307 · Cited by 57
Bedse, G., Romano, A., Tempesta, B., Lavecchia, A. M., Pace, L., Bellomo, A., Duranti, A., Bonaventura, M. V. M. D., Cifani, C., Cassano, T., et al. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23539 · Cited by 34
“URB597 elicits marked anxiolytic- and antidepressant-like effects in rodents (Kathuria et al., 2003; Gobbi et al., 2005).”
BackgroundMethodInfluentialSelf-citationSu, S., Wu, Y.-F., Lin, Q., Yu, F., & Hai, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.021 · Cited by 33
Morais, H., Chaves, Y. C., Waltrick, A. P. F., Jesus, C. H. A., Genaro, K., Crippa, J. A. S., da Cunha, J. M., & Zanoveli, J. M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.006 · Cited by 35
Slivicki, R. A., Xu, Z., Mali, S. S., & Hohmann, A. G. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.002 · Cited by 33
“By contrast, FAAH inhibitors show efficacy in preclinical models of pain [8,9], nausea [10], and anxiety [11,12] without the occurrence of tolerance [6,13].”
BackgroundMethodZhang, M., Ruwe, D., Saffari, R., Kravchenko, M., & Zhang, W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00091 · Cited by 31
Rocha, L., Çınar, R., Guevara‐Guzmán, R., Alonso‐Vanegas, M., San‐Juan, D., Martínez-Juárez, I. E., Castañeda‐Cabral, J. L., & Carmona-Cruz, F. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.00052 · Cited by 33
Endocannabinoid-serotonin systems interaction in health and disease
Colangeli, R., Teskey, G. C., & Giovanni, G. D. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.003 · Cited by 34
Fowler, C. J., Doherty, P., & Alexander, S. P. H. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.03.006 · Cited by 40
“Early studies using FAAH inhibitors and FAAH-/- mice demonstrated that, providing enzyme activity was sufficiently inhibited, brain levels of AEA were dramatically increased (Cravatt et al., 2001; Kathuria et al., 2003).”
BackgroundRock, E. M., Limebeer, C. L., Ward, J. M., Cohen, A., Grove, K., Niphakis, M. J., Cravatt, B. F., & Parker, L. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4050-7 · Cited by 31
Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats
de Carvalho, C. R., Pamplona, F. A., Cruz, J. S., & Takahashi, R. N. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3331-2 · Cited by 34
“), although it produces anxiolytic (Kathuria et al. 2003) and antidepressant effects (Gobbi et al. 2005) in rodents.”
McKinney, M. K., & Cravatt, B. F. (2006) · Biochemistry · doi:10.1021/bi0608010 · Cited by 32
Melis, M., Greco, B., & Tonini, R. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12501 · Cited by 33
“…FAAH (e.g. with the compound URB597) and genetic deletion of FAAH not only enhance NAE levels, but also amplify eCB effects (Cravatt et al., 2001; Kathuria et al., 2003; Fegley et al., 2005) via activation of a-peroxisome proliferator-activated receptor (Jhaveri et al., 2008; Melis et al., 2008;…”
BackgroundLester, K. J., Coleman, J. R. I., Roberts, S., Keers, R., Breen, G. D., Bögels, S. M., Creswell, C., Hudson, J. L., McKinnon, A., Nauta, M. H., et al. (2016) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32467 · Cited by 33
“There is also suggestive evidence that targeting components of the ECB system via activation of CB1 receptors or by manipulating FAAH activity may produce anxiolytic effects [Kathuria et al., 2003; Lafenetre et al., 2007; Gunduz-Cinar et al., 2013].”
BackgroundAguilar, D. D., Giuffrida, A., & Lodge, D. J. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy003 · Cited by 32
“In rodents, this dose of URB597 inhibits FAAH in vivo and upregulates brain endocannabinoid anandamide for hours without producing changes in locomotion, body temperature, or food intake (Kathuria et al., 2003).”
BackgroundWise, L. E., Harloe, J. P., & Lichtman, A. H. (2009) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2009.06.001 · Cited by 34
“…Ledent, & Freund, 2002; Patel & Hillard, 2006; Rodgers, Evans, & Murphy, 2005; Scherma et al., 2008), whereas pharmacological inhibitors of FAAH can produce anxiolytic-like responses (Bortolato et al., 2006; Kathuria et al., 2003; Naidu et al., 2007; Patel & Hillard, 2006; Scherma et al., 2008).”
Walther, A., Kirschbaum, C., Wehrli, S., Rothe, N., Penz, M. S., Wekenborg, M., & Gao, W. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110658 · Cited by 31
Sandberg, A., & Fowler, C. J. (2005) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2004.12.010 · Cited by 30
Chauvet, C., Nicolas, C., Thiriet, N., Lardeux, V., Duranti, A., & Solinas, M. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu025 · Cited by 32
“Administration of URB597 has been shown to have positive effects against anxiety (Kathuria et al., 2003), depression (Gobbi et al.”
BackgroundInfluentialSelf-citationBehavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms
Shahidi, ., & Hasanein, P. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.06.019 · Cited by 32
García‐Gutiérrez, M. S., & Manzanares, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109106910 · Cited by 32
“…results in anxiolytic action in rodents that is blocked by previous administration with cannabinoid CB1 receptor antagonists (Bortolato et al., 2006; Gaetani et al., 2003; Kathuria et al., 2003; Moreira et al., 2008; Patel and Hillard, 2006; Rutkowska et al., 2006; Scherma et al., 2008).”
Background
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.